Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most
difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream …

Within a tumor, IL-1β is produced and secreted by various cell types, such as immune cells,
fibroblasts, or cancer cells. The IL1B gene is induced after “priming” of the cells and a …

Activation of the Nod-like receptor family pyrin domain containing 3 (NLRP3) inflammasome
drives release of the proinflammatory cytokines interleukin (IL)-1 β and IL-18 and induces …

Inflammation is involved in tumor development and progression as well as antitumor
response to therapy. In the past decade, the crosstalk between inflammation, immunity, and …

Inflammasomes are large protein complexes that play a major role in sensing inflammatory
signals and triggering the innate immune response. Each inflammasome complex has three …

Inflammation, when properly mounted and precisely calibrated, is a beneficial process that
enables the rapid removal of invading pathogens and/or cellular corpses and promotes …

IRAK-targeted therapies that have matriculated to early phase trials are yielding promising
preliminary results. However, studies of IRAK kinase signaling continue to defy conventional …

Numerous preclinical and clinical studies have demonstrated the significant contribution of
inflammation to the development and progression of various types of cancer. Inflammation in …

Introduction Covalent drugs have been used for more than hundred years, but gathered
larger interest in the last two decades. There are currently over a 100 different electrophilic …